Literature DB >> 24696332

Pseudo-infectious reporter virus particles for measuring antibody-mediated neutralization and enhancement of dengue virus infection.

Swati Mukherjee1, Theodore C Pierson, Kimberly A Dowd.   

Abstract

This chapter outlines methods for the production of dengue virus (DENV) reporter virus particles (RVPs) and their use in assays that measure antibody-mediated neutralization and enhancement of DENV infection. RVPs are pseudo-infectious virions produced by complementation of a self-replicating flavivirus replicon with the DENV structural genes in trans. RVPs harvested from transfected cells are capable of only a single round of infection and encapsidate replicon RNA that encodes a reporter gene used to enumerate infected cells. RVPs may be produced using the structural genes of different DENV serotypes, genotypes, and mutants by changing plasmids used for complementation. Further modifications are possible including generating RVPs with varying levels of uncleaved prM protein, which resemble either the immature or mature form of the virus. Neutralization potency is measured by incubating RVPs with serial dilutions of antibody, followed by infection of target cells that express DENV attachment factors. Enhancement of infection is measured similarly using Fc receptor-expressing cells capable of internalizing antibody-virus complexes.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24696332     DOI: 10.1007/978-1-4939-0348-1_6

Source DB:  PubMed          Journal:  Methods Mol Biol        ISSN: 1064-3745


  18 in total

1.  Recurrent Potent Human Neutralizing Antibodies to Zika Virus in Brazil and Mexico.

Authors:  Davide F Robbiani; Leonia Bozzacco; Jennifer R Keeffe; Ricardo Khouri; Priscilla C Olsen; Anna Gazumyan; Dennis Schaefer-Babajew; Santiago Avila-Rios; Lilian Nogueira; Roshni Patel; Stephanie A Azzopardi; Lion F K Uhl; Mohsan Saeed; Edgar E Sevilla-Reyes; Marianna Agudelo; Kai-Hui Yao; Jovana Golijanin; Harry B Gristick; Yu E Lee; Arlene Hurley; Marina Caskey; Joy Pai; Thiago Oliveira; Elsio A Wunder; Gielson Sacramento; Nivison Nery; Cibele Orge; Federico Costa; Mitermayer G Reis; Neena M Thomas; Thomas Eisenreich; Daniel M Weinberger; Antonio R P de Almeida; Anthony P West; Charles M Rice; Pamela J Bjorkman; Gustavo Reyes-Teran; Albert I Ko; Margaret R MacDonald; Michel C Nussenzweig
Journal:  Cell       Date:  2017-05-04       Impact factor: 41.582

2.  Broadly Neutralizing Activity of Zika Virus-Immune Sera Identifies a Single Viral Serotype.

Authors:  Kimberly A Dowd; Christina R DeMaso; Rebecca S Pelc; Scott D Speer; Alexander R Y Smith; Leslie Goo; Derek J Platt; John R Mascola; Barney S Graham; Mark J Mulligan; Michael S Diamond; Julie E Ledgerwood; Theodore C Pierson
Journal:  Cell Rep       Date:  2016-07-29       Impact factor: 9.423

3.  Infection by Zika viruses requires the transmembrane protein AXL, endocytosis and low pH.

Authors:  Mirjana Persaud; Alicia Martinez-Lopez; Cindy Buffone; Steven A Porcelli; Felipe Diaz-Griffero
Journal:  Virology       Date:  2018-03-22       Impact factor: 3.616

4.  Pseudovirus-Based Assays for the Measurement of Antibody-Mediated Neutralization of SARS-CoV-2.

Authors:  Corey Balinsky; Vihasi Jani; Peifang Sun; Maya Williams; Gabriel Defang; Kevin R Porter
Journal:  Methods Mol Biol       Date:  2022

5.  Implications of a highly divergent dengue virus strain for cross-neutralization, protection, and vaccine immunity.

Authors:  Rita E Chen; Brittany K Smith; John M Errico; David N Gordon; Emma S Winkler; Laura A VanBlargan; Chandni Desai; Scott A Handley; Kimberly A Dowd; Emerito Amaro-Carambot; M Jane Cardosa; Carlos A Sariol; Esper G Kallas; Rafick-Pierre Sékaly; Nikos Vasilakis; Daved H Fremont; Stephen S Whitehead; Theodore C Pierson; Michael S Diamond
Journal:  Cell Host Microbe       Date:  2021-10-04       Impact factor: 31.316

6.  Zika Virus Circulates at Low Levels in Western and Coastal Kenya.

Authors:  Theodore A Gobillot; Caroline Kikawa; Dara A Lehman; John Kinuthia; Alison L Drake; Walter Jaoko; Kishorchandra Mandaliya; Grace John-Stewart; R Scott McClelland; Julie Overbaugh
Journal:  J Infect Dis       Date:  2020-08-04       Impact factor: 5.226

7.  Enhancing dengue virus maturation using a stable furin over-expressing cell line.

Authors:  Swati Mukherjee; Devika Sirohi; Kimberly A Dowd; Zhenguo Chen; Michael S Diamond; Richard J Kuhn; Theodore C Pierson
Journal:  Virology       Date:  2016-07-13       Impact factor: 3.616

8.  Dengue vaccine breakthrough infections reveal properties of neutralizing antibodies linked to protection.

Authors:  Sandra Henein; Cameron Adams; Matthew Bonaparte; Janice M Moser; Alina Munteanu; Ralph Baric; Aravinda M de Silva
Journal:  J Clin Invest       Date:  2021-07-01       Impact factor: 19.456

9.  A single mutation in the envelope protein modulates flavivirus antigenicity, stability, and pathogenesis.

Authors:  Leslie Goo; Laura A VanBlargan; Kimberly A Dowd; Michael S Diamond; Theodore C Pierson
Journal:  PLoS Pathog       Date:  2017-02-16       Impact factor: 6.823

10.  Epitope Addition and Ablation via Manipulation of a Dengue Virus Serotype 1 Infectious Clone.

Authors:  Emily N Gallichotte; Vineet D Menachery; Boyd L Yount; Douglas G Widman; Kenneth H Dinnon; Steven Hartman; Aravinda M de Silva; Ralph S Baric
Journal:  mSphere       Date:  2017-02-22       Impact factor: 4.389

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.